QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
Quiz night!
Although we didn’t win the obscenely difficult quiz night on Tuesday (there wasn’t even one question about health economics or epidemiology!), the Quantify team did score highest in team spirit.
Thanks for another great ISPE annual!
Jessica Young from Quantify Research’s Stockholm office had a fantastic time at last week’s International Society for Pharmacoepidemiology‘s annual meeting, reconnecting with colleagues, meeting new faces, and diving into engaging discussions around the role of pharmacoepidemiology in supporting healthcare decision making.
Do any of Jess’s sessions catch your eye? Don’t hesitate to reach out and learn more.
We’re already looking ahead to ISPE 2025 in […]
Plant-afternoon
Last week the team came together to give the office plants some much needed TLC.
Turns out there are a fair few green fingers at Quantify!
Whilst we might not be adding gardening to our service offering any time soon, we hope that visitors to the Stockholm office will enjoy our jungle of plants just as much as we do.
Quantify investigates intensified cytarabine dosing in high-risk AML
Quantify’s Mathias Lilja and Johan Mesterton are co-authors on a new study on cytarabine dosing for treating secondary and high-risk AML using a synthetic control arm study design.
Since 1980’s, the standard treatment of acute myeloid leukemia (AML) is cytarabine infusion with anthracycline (7 + 3 regimen). Our latest research at Quantify aimed to assess if higher cytarabine dosing in induction may provide a benefit in older patients with secondary and high-risk […]